About CLINUVEL

SCENESSE® and its use in vitiligo - Lee Thomas and Dr Philippe Wolgen, Part 1

06 Aug 2012

Taking on Vitiligo, a depigmentation disorder of the skin.

In 2010, CLINUVEL ventured into an area of dermatology where no other pharmaceutical company has yet succeeded, trialing a new drug, SCENESSE® (afamelanotide) in vitiligo as a combination therapy with narrowband ultraviolet B light therapy.

Winner of four Emmy® Awards, anchor and producer, entertainment reporter at WJBK Fox 2 Detroit, Mr Lee Thomas is a spokesperson for the US vitiligo community.

In this four part video series, shot in early 2012, he interrogated CLINUVEL’s CEO Dr Philippe Wolgen about SCENESSE® as a potential remedy in vitiligo.

Learn more about CLINUVEL's vitiligo program

Quick Links